Company Interview / Not your typical Aussie biotech, Firebrick grows its sales & footprint

Firebrick Pharma's CEO and Executive Chair Peter Molloy highlights the commercial success of its Nasodine nasal spray, a product targeting germs responsible for respiratory infections. The spray is gaining traction in multiple markets, including Singapore which has enabled rapid market entry without regulatory delays. Molloy explains how Singapore is acting as a springboard for entry into other markets across the region.

The company's goal is to expand sales through licensing agreements in Asia-Pacific, notably in Fiji and the Philippines, which will allow it to enhancing profitability without direct manufacturing or marketing costs. Molloy says Firebrick Pharma (ASX: FRE) is well and truly shifting focus from R&D to commercialisation, reducing cash burn in 2025. Future goals include releasing new products by year-end and further market expansion.

Molloy says the recent share price lift reflects investors' confidence in the company's strategic evolution.